explore -WSS

explore

author：Wikipedia 2025-09-03 09:37:17 - browse：72

An orange Flovent inhaler on a white background. -- health coverage from STAT — Adobe

As of Jan. 1, thousands of asthma patients in the U.S. will no longer be able to get refills for Flovent — one of the most popular inhalers in the U.S. for nearly 30 years.

Flovent’s manufacturer, GSK, has discontinued both versions of the product — Flovent HFA, an inhalation aerosol, and Flovent Diskus, an inhalation powder — and replaced each with what is known as an “authorized generic,” essentially the same product sold under a private label. Prasco, a U.S. drugmaker specializing in authorized generics, will distribute the new inhaler, sold as fluticasone.

The timing of the change is telling: Flovent’s price rose nearly 50% since 2014, according to GoodRx, leaving the drug vulnerable to the new Medicaid penalties going into effect as of this year for medications with price increases that outpace inflation. By discontinuing the brand-name inhaler but continuing to earn money from the authorized generic, GSK will be able to avoid paying a penalty.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Was Amgen transparent enough on FDA's concern on cancer drug?

hotspot

WSS

HIV vaccine remains elusive. Immunologists keep trying new ideas

Solving academic medical centers' existential crisis

Military medical care influenced by rank and race, new study finds

Analysis of telehealth claims data suggest service duplication

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Cytokinetics CEO stresses company can launch heart drug on its own

knowledge

explore

focus

ChatGPT in medicine: STAT answers readers' burning questions

Senate panel eyes new effort on drug shortages

Hepatitis C has a cure — but many Americans still lack access to it

Second House panel advances two

ChatGPT in medicine: STAT answers readers' burning questions

Phenylephrine and the overlooked value of the placebo effect

Heart attack and stroke risk calculators need revising

Military medical care influenced by rank and race, new study finds

How to save PrEP access — and even expand it

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

hotspot

Chan Zuckerberg Biohub Chicago to focus on inflammation

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Arc Institute generative AI designs new CRISPR systems

Histogen: Failed biotech offers rare public look inside

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

VC firm General Catalyst wants to buy a health system

focus

hotspot

focus

hotspot